Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PF-4989216 是一种有效的选择性 PI3K 抑制剂,对 p110α、p110β、p110γ、p110δ 和 VPS34 的 IC50 分别为 2 nM、142 nM、65 nM、1 nM 和 110 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 283 | 现货 | ||
2 mg | ¥ 395 | 现货 | ||
5 mg | ¥ 662 | 现货 | ||
10 mg | ¥ 1,060 | 现货 | ||
25 mg | ¥ 1,990 | 现货 | ||
50 mg | ¥ 3,230 | 现货 | ||
100 mg | ¥ 5,170 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 728 | 现货 |
产品描述 | PF-4989216 is a potent and selective PI3K inhibitor with IC50 of 2 nM, 142 nM, 65 nM, 1 nM, and 110 nM for p110α, p110β, p110γ, p110δ, and VPS34, respectively. |
靶点活性 | p110α:2 nM, p110γ:65 nM, p110δ:1 nM, p110β:142 nM, VPS34:110 nM |
体外活性 | PF-4989216 significantly inhibits cell viability in SCLC cells with a PIK3CA mutation, such as NCI-H69, NCI-H1048, and Lu99A cells. PF-4989216, via PI3K signaling inhibition, blocks cell-cycle progression and reduces cell transformation in SCLCs. In SCLCs with PIK3CA mutation, PF-4989216 induces BIM-mediated apoptosis. [1] |
体内活性 | In SCID mice bearing NCI-H69 or NCI-H1048 xenograft tumors, PF-4989216 (350 mg/kg, p.o.) inhibits PI3K phosphorylation signaling and induces antitumor activity. [1] |
细胞实验 | SCLC cells are cultured (5,000 cells/well) in a 96-well microtiter plate at 37°C in 5% CO2 in supplier-recommended growth media and compounds are added to each well starting at 10 μM with a 3-fold serial dilution. At 72 hours after compound addition, CellTiter-Glo (CTG) Solution is added per the manufacturer's instructions. Luminescence is read on an Envision plate reader. All experiments are run in duplicate and have been repeated at least three times.(Only for Reference) |
别名 | PF 4989216 |
分子量 | 380.4 |
分子式 | C18H13FN6OS |
CAS No. | 1276553-09-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 7 mg/mL (18.4 mM), Heating is recommended.
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 71 mg/mL (186.6 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol / DMSO | 1 mM | 2.6288 mL | 13.1441 mL | 26.2881 mL | 65.7203 mL |
5 mM | 0.5258 mL | 2.6288 mL | 5.2576 mL | 13.1441 mL | |
10 mM | 0.2629 mL | 1.3144 mL | 2.6288 mL | 6.572 mL | |
DMSO | 20 mM | 0.1314 mL | 0.6572 mL | 1.3144 mL | 3.286 mL |
50 mM | 0.0526 mL | 0.2629 mL | 0.5258 mL | 1.3144 mL | |
100 mM | 0.0263 mL | 0.1314 mL | 0.2629 mL | 0.6572 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
PF-4989216 1276553-09-3 Apoptosis PI3K/Akt/mTOR signaling PI3K inhibit Phosphoinositide 3-kinase PF4989216 Inhibitor PF 4989216 inhibitor